Emergent BioSolutions Downgraded as Narcan Sales Wane and Debt Remains a Concern
On September 6, 2026, Emergent BioSolutions Inc. (NYSE: EBS) slipped from a Buy to a Hold rating when Seeking Alpha anal...
Read story →
On September 6, 2026, Emergent BioSolutions Inc. (NYSE: EBS) slipped from a Buy to a Hold rating when Seeking Alpha anal...
Read story →
When Wellington City Council announced a $595,801 contract with Auckland‑based Journey Digital to design and build a n...
Read story →